FY2025 · ended Dec 31, 2025 · Revenue $70.85M, +23359.9% YoY · Filed Feb 26, 2026
Viridian Therapeutics, Inc./DE (VRDN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $70.8 million and a net loss of $342.6 million. Free cash flow was -$276.9 million. As of Sep 30, 2026 it held $955.2 million in cash and investments and $806,000 in total debt.
Revenue (TTM)
$26.31M
-62.8% vs year-ago TTM
Net income (TTM)
$-453.58M
-50.2% vs year-ago TTM
Operating cash flow (TTM)
$-341.50M
-4.8% vs year-ago TTM
Free cash flow (TTM)
$-343.44M
-5.2% vs year-ago TTM
EPS
$-5.31
-31.1% vs prior year
Dividend per share
None
Shares outstanding
102.21M
+25.4% vs prior year
Net cash
$954.40M
as of Sep 30, 2026
Operating margin
-1781.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRDN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1590750
- Former names
- MIRAGEN THERAPEUTICS, INC. (until Jan 15, 2021); SIGNAL GENETICS, INC. (until Feb 10, 2017); SIGNAL GENETICS LLC (until Jul 9, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $70.8M | $302,000 | $314,000 | $1.8M | $3.0M |
| Operating income | -$363.4M | -$299.0M | -$254.4M | -$134.3M | -$79.7M |
| Net income | -$342.6M | -$269.9M | -$237.7M | -$129.9M | -$79.4M |
| Diluted EPS | — | — | -$5.31 | -$4.05 | -$6.66 |
| Operating cash flow | -$276.4M | -$232.3M | -$184.2M | -$93.8M | -$54.6M |
| Free cash flow | -$276.9M | -$232.8M | -$185.1M | -$94.6M | -$54.9M |
| Total assets | $899.4M | $742.4M | $490.4M | $435.1M | $203.7M |
| Total liabilities | $177.3M | $70.8M | $48.4M | $40.0M | $16.0M |
| Stockholders' equity | $722.2M | $671.6M | $442.0M | $395.1M | $187.7M |
| Cash and investments | $874.7M | $717.6M | $477.4M | $424.6M | $197.0M |
| Total debt | $2.7M | $23.1M | $22.0M | $6.4M | $1.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 29, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2026 | Jun 2, 2026 |
All 817 Viridian Therapeutics, Inc./DE SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.